Pages

Thursday, 24 June 2021

16 Jun 21 Sputnik V vaccine EU approval delayed

EU approval of Russia's Sputnik V vaccine delayed — sources

 European Union approval of Russia's Sputnik V coronavirus vaccine will be delayed because a June 10 deadline to submit clinical trial data was missed ...



BERLIN (June 16): European Union approval of Russia's Sputnik V coronavirus vaccine will be delayed because a June 10 deadline to submit data was missed, two people familiar with the matter told Reuters, diminishing the shot's prospects in the EU's pandemic response.

One of the sources, a German government official, said the failure to provide the necessary clinical trial data to the EU medicines watchdog would postpone any go-ahead in the bloc until at least September.

"Approval of Sputnik will be delayed probably until September, maybe until the end of the year," the official said, speaking on condition of anonymity.

The European Medicines Agency (EMA) had previously been expected to conclude its review of the Russian vaccine and issue a decision in May or June.

A second source said the June 10 cut-off date was not met and that the vaccine's developer, Russia's Gamaleya Institute, said it will file the requested data next week or at the latest at the end of the month.

The Russian Direct Investment Fund (RDIF), which markets the vaccine, said the EMA review was on track.

"All of the information on the Sputnik V vaccine clinical trials has been provided and GCP (General Clinical Practice) review has been completed with positive feedback from the European Medicines Agency," the RDIF said.

"While it is up to EMA to decide on the timing of the approval procedure, the Sputnik V team expects the vaccine approval with the next two months," it added.

EMA was not immediately available for comment.

German Chancellor Angela Merkel's government has held talks to buy Sputnik V but has made any purchase contingent on EMA approval.

Frustrated by a sluggish immunisation campaign, some regional German states including Bavaria earlier this year flagged interest in placing orders for Sputnik V, but vaccination has since picked up speed.

Slovakia became the EU's second country after Hungary to start inoculating people with Sputnik V this month, despite lack of EU approval.

https://www.theedgemarkets.com/article/eu-approval-russias-sputnik-v-vaccine-delayed-%E2%80%94-sources-0


WHO, EMA to inspect Sputnik V manufacturing in May — WHO

Stephanie Nebehay/
Reuters

April 22, 2021 18:55 pm +08


GENEVA (April 22): Technical experts from the World Health Organization (WHO) are due to start the next round of their review of Russia's Sputnik V vaccine against Covid-19 jointly with the European Medicines Agency (EMA) on May 10, the WHO said on Thursday.

Russia is seeking WHO emergency-use listing for the vaccine developed by Gamalaya Institute. So far Covid-19 vaccines made by Pfizer, AstraZeneca, and Johnson & Johnson have been listed — an endorsement of their safety and efficacy that helps guide countries' regulatory systems.

"Inspections for good manufacturing practices will take place from 10 May to first week of June," the WHO told Reuters in reply to a query.

A joint team from the WHO and the EMA are currently carrying out inspections for good clinical practices related to Sputnik V, it said.

Asked about clinical data from Sputnik V vaccine trials, the WHO said: "We are still receiving information from the producer."

Russian deputy health minister Sergei Vershinin held talks in Geneva on Tuesday with WHO director-general Tedros Adhanom Ghebreyesus, who later wrote on Twitter: "@WHO appreciates Russia's efforts to fulfill the Emergency Use Listing criteria for vaccines."

https://www.theedgemarkets.com/article/who-ema-inspect-sputnik-v-manufacturing-may-%E2%80%94-who

Tuesday, 22 June 2021

21 Jun 21 S'pore Concerned About Sinovac Covid-19 Vaccine After ...

Singapore Concerned About Sinovac Covid-19 Vaccine After Hundreds Of Indonesian Healthcare Workers Tests Positive

·4-min read


Evaluating the experience of countries such as Indonesia, Sinovac's CoronaVac poses considerable risk of "vaccine breakthrough," says Singapore Ministry of Health's Director of Medical Services, Kenneth Mak.

Made-in-China vaccines have again raised concern after more than 350 healthcare professionals contracted novel coronavirus in Indonesia despite being vaccinated with the World Health Organization (WHO) approved Sinovac jab, officials said.

Badai Ismoyo, head of the health office in the district of Kudus in Central Java, said that most of these infected people were asymptomatic and self-isolating at home. But dozens of people have been admitted to hospitals with high fevers and low oxygen saturation levels. It was also reported that Kudus, which has around 5,000 people working in healthcare, is dealing with an outbreak caused by the more transmissible Delta variant, which has pushed bed occupancy rates beyond 90 per cent.

Healthcare workers, who were designated as a priority category, were among the first to be vaccinated when vaccinations began in January this year. According to the Indonesian Medical Association, almost everyone has received the Covid-19 vaccination made by the Chinese biopharmaceutical company Sinovac.

Between January and May, the number of healthcare workers in Indonesia dying from Covid-19 declined from 158 to 13. But the public health experts said that the unprecedented hospitalisation numbers in Java are concerning.

As per the WHO, a large Phase III trial in Brazil found that two doses, given 14 days apart, had a 51 per cent efficacy against symptomatic coronavirus infection, a 100 per cent efficacy against severe Covid-19 and a 100 per cent efficacy against hospitalisation commencing 14 days following the second dose.

It was also said that in an observational study, “the estimated effectiveness of Sinovac vaccine CoronaVac in health workers in Manaus, Brazil, where P.1 (Gamma variant) accounted for 75 per cent of SARS-CoV-2 samples was 49.6 per cent against symptomatic infection. Effectiveness has also been shown in an observational study in Sao Paulo in the presence of P.1 circulation (83 per cent of samples)”.

According to the WHO website, assessments in settings where the P.2 or Zeta variant was widely circulating in Brazil estimated vaccine effectiveness of 49.6 per cent following at least one dose of the vaccine and demonstrated 50.7 per cent two weeks after the second dose.

But Dicky Budiman, an epidemiologist at Australia's Griffith University told CNN: "The data shows they have the Delta variant (in Kudus) so it is no surprise that the breakthrough infection is higher than before, because, as we know, the majority of healthcare workers in Indonesia got Sinovac, and we still don't know yet how effective it is in the real world against the Delta variant”.

Amid one of Asia's worst outbreaks, with over 1.9 million infections and 53,000 deaths, Indonesia's doctors and nurses have suffered a heavy toll of 946 fatalities. Despite being vaccinated, at least five doctors and one nurse have died from Covid-19 in Indonesia. Dr Prijo Sidipratomo, a radiologist in Jakarta said that he knew of at least half a dozen doctors who had been hospitalised with Covid-19 despite having vaccinated in the previous month, with one still being treated in an ICU. He said: "It is alarming for us because we cannot rely on vaccinations only".

Apart from Indonesia, some other countries also witnessed a spike in cases even after launching a vaccination drive using Chinese jabs developed by Sinovac and Sinopharm. On 18 June, the Singapore Ministry of Health's (MOH) director of medical services, Kenneth Mak, said that the Sinovac’s CoronaVac poses a considerable risk of "vaccine breakthrough," with international evidence indicating that many people who received it later became sick with Covid-19.

While speaking to reporters at a virtual media briefing—while responding to questions on whether Singapore will introduce Sinovac jabs into the national vaccination program—Mak said that the authority has been evaluating the experience of countries such as Indonesia, which has used CoronaVac to vaccinate a "larger proportion" of the population.

According to him, "It's not a problem associated with Pfizer. This is actually a problem associated with the Sinovac vaccine, and in other countries, they are now starting to think about booster vaccinations, even six months out from an original vaccination for some of these vaccines as well”.

It gives the idea that the performance of different vaccinations will vary very dramatically, Mak said while adding that Singapore has "great confidence" in the Pfizer-BioNTech, as well as Moderna vaccines, of which over 4.7 million doses have been administered in the South-East Asian country.

Singapore MOH has granted licences to 24 healthcare institutions to distribute the Sinovac vaccine to anyone who chooses to get it. These institutions were chosen as licenced providers under the Special Access Route (SAR) under the Private Hospitals and Medical Clinics Act (PHMCA). However, Sinovac remains unregistered by the Health Sciences Authority (HSA) and will only be available through the SAR framework. It means that it will not be covered by the Vaccine Injury Financial Assistance Program (VIFAP), which is intended for the national vaccination programme.

https://in.news.yahoo.com/singapore-concerned-sinovac-covid-19-075644453.html

'Overwhelming' response for Sinovac COVID-19 vaccine at some approved clinics

 SINGAPORE: Several clinics received hundreds of enquiries about the Sinovac COVID-19 vaccine on Thursday (Jun 17), a day after the Ministry of Health (MOH) released its list of approved clinics to administer the shots.

(Updated: )ggle share menu

  1. demand for sinovac shots at clinics


When CNA visited Wee Healthfirst Medical Clinic in Clementi - one of the 24 approved clinics - at about 2.30pm on Thursday, at least 15 people were there to ask about the Sinovac vaccine.

Staff members were seen handing out paper slips for people to leave their details so that the clinic could contact them once the shots were available. Nearly 1,000 names were given to the clinic, according to the clinic’s director Dr Seow Yu Jin.

"It's just been manic, it's been very busy ... Some patients, unfortunately, couldn't get through on the phone and had to personally come down and there was a long queue outside of the clinic, which I really wasn't expecting," said Dr Seow.

READ: 24 clinics selected to administer Sinovac COVID-19 vaccine; S$10 to S$25 for single dose

He said the clinic is currently waiting for its first batch of Sinovac shots to arrive.

"Hopefully they (the vaccine shots) will come tomorrow. We're bedding down processes – tonight, I'm just going to finalise my patient leaflets and then hopefully start vaccinating by the weekend," he said.

He added that the clinic plans to open outside its usual operating hours in order to administer the vaccine.

"For example, this weekend, my Saturday clinic will run from 8am to 1pm. In order to deal with this response, we will probably have to open after 1pm until about 5pm, 6pm, when we can just purely vaccinate, just get through the numbers," he said.

READ: Some Singapore private healthcare providers consider offering Sinovac's COVID-19 vaccine after WHO approval

It was a similar situation at StarMed Specialist Centre, an ambulatory surgery centre in Farrer Park, which has seen an “overwhelming” response since its phone lines opened at 8am on Thursday.

“We've already had (more than) 400 bookings for vaccinations,” the centre’s chief executive officer Dr Louis Tan told CNA.

"It's fair to say that we have seen a larger number of patients who are above the age of 40 make enquiries as to these vaccinations," he added.

The centre has placed an order of 1,000 doses of the Sinovac vaccine, which was the maximum amount it was allowed, according to Dr Tan. It will be receiving 200 doses, with the first batch expected on Friday. 

To cope with the demand, the centre intends to bring in more nurses to support its current staff members, he said. At the moment, the centre does not plan to extend its operating hours, but it will do so if necessary, said Dr Tan.

When CNA tried calling the other clinics on the approved list between 3pm and 5pm, most of the phone lines were busy.

Two of them who picked up - iCare Medical and Wellness Clinic, and Chinatown Wellness - told CNA that they were “swamped” with enquiries from the public, but did not give figures.

Meanwhile, Pinnacle Family Clinic’s Pasir Ris branch told CNA it has received more than 200 enquiries over the phone about the vaccine.

READ: Sinovac COVID-19 vaccine to be allowed in Singapore under special access route after WHO approval

StarMed Specialist Centre, which was involved in the vaccination of migrant workers and provided medical support at various community care facilities, said it will apply the same safety precautions when administering the Sinovac jabs. 

"(We will screen) patients for recent illness, fever ... possibility of pregnancy and so forth, as well as filtering them by age, these are all standard questions that we would ask patients before we administer the vaccine," said Dr Tan.

He added that the centre was waiting for more guidelines from MOH.

MOH sinovac clinics
(Table: MOH)

MOH reiterated on Wednesday that the Sinovac vaccine is not part of the national vaccine programme and those taking the Sinovac jabs will not be covered under the Vaccine Injury Financial Assistance Programme for COVID-19 Vaccination.

The ministry added that those who wish to receive the vaccine through the Special Access Route should discuss the risks and benefits with their doctors at their selected private healthcare institutions.

https://www.channelnewsasia.com/news/singapore/covid-19-sinovac-vaccine-jab-clinics-overwhelming-response-15033550


  1. Media tour at Chinese vaccine maker Sinovac Biotech in Beijing

    Sinovac CEO complained about anti-China comments in Brazil: Report

    The chief executive of Sinovac Biotech, the main supplier of COVID-19 vaccines to Brazil, complained last month to Brazilian diplomats in Beijing ...
  2. Singapore COVID-19 vaccine vaccination MOE schools students 4

    Commentary: Inaccurate public understanding of COVID-19 vaccine efficacy has implications for vaccination rates

    High vaccination uptake is key to easing COVID-19 restrictions, but a majority of polled respondents misunderstand how much protection vaccines ...
  3. FILE PHOTO: China's vaccine specialist CanSino Biologics Inc in Tianjin

    China to study using CanSinoBIO COVID-19 shots as a booster

    Chinese researchers plan to study using a COVID-19 vaccine from CanSino Biologics as a booster shot for people who have already been inoculated ...